Assessment of the Involvement of CYP3A in the Vitro Metabolism of a New Modulator of MDR in Cancer Chemotherapy, OC144-193, by Human Liver Microsomes

Overview

Journal Eur J Drug Metab Pharmacokinet

Date 2002 Jan 26

PMID 11808870

Citations 3

Authors

E S Guns

P L Bullock

M L Reimer

R Dixon

M Bally

L D Mayer

Affiliations

Soon will be listed here.

Abstract

The novel substituted imidazole compound, OC144-093 exhibits potent biological activity in vitro and in vivo for reversal of P-glycoprotein (PgP) based resistance to cancer chemotherapy. Its mechanism of action relies upon its inhibitory interaction with the mdr1 gene product, a known mediator of multidrug resistance (MDR). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A (CYP3A) and PgP indicate the potential for drug-drug interactions when modulator and anticancer agent are co-administered. We have examined the metabolism of OC144-093 in vitro using human liver microsomes to determine if CYP3A is involved. Our results show that OC144-093 is converted to one major metabolite (M1) in human liver microsomes which was identified by LCMS to be the O-deethylated derivative. Km and Vmax for O-deethylation were determined as 3.96+/-0.67 microM and 32.08+/-9.73 pmol/mg protein/min, respectively (n=3). Correlation studies conducted in a panel of human livers phenotyped for specific P450 enzyme activity showed a significant relationship between M1 formation and the activity of CYP2C9, CYP2B6, CYP2E1 and CYP3A4. Treatment of microsomes with carbon monoxide gas inhibited M1 formation and diethyldithiocarbamate and ketoconazole (>3 microM), non-specific CYP inhibitors, gave IC50 values of 124.4+/-21.6 microM and 25.3+/-3.2 microM respectively for the inhibition of O-deethylation, also implicating the involvement of CYP enzymes. Specific CYP inhibitors of CYP3A4 were essentially non-inhibitory to M1 formation. We can conclude therefore that OC144-093 is not extensively metabolised in human liver microsomes although conversion to its O-deethylated derivative does occur. Our data indicates that this conversion is not mediated by CYP3A4.

Citing Articles

The reversal of antineoplastic drug resistance in cancer cells by β-elemene.

Zhang G, Ashby Jr C, Zhang Y, Chen Z, Guo H Chin J Cancer. 2015; 34(11):488-95.

PMID: 26370907 PMC: 4593349. DOI: 10.1186/s40880-015-0048-0.

Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.

Dai C, Liang Y, Chen L, Zhang X, Deng W, Su X Biochem Pharmacol. 2009; 78(4):355-64.

PMID: 19410561 PMC: 2798597. DOI: 10.1016/j.bcp.2009.04.023.

Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy.

Guns E, Denyssevych T, Dixon R, Bally M, Mayer L Eur J Drug Metab Pharmacokinet. 2002; 27(2):119-26.

PMID: 12064370 DOI: 10.1007/BF03190426.

References

Kumar G, Walle U, Walle T . Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther. 1994; 268(3):1160-5. View

Murray G, McKay J, Weaver R, Ewen S, Melvin W, Burke M . Cytochrome P450 expression is a common molecular event in soft tissue sarcomas. J Pathol. 1993; 171(1):49-52. DOI: 10.1002/path.1711710110. View

CHANG T, Gonzalez F, Waxman D . Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys. 1994; 311(2):437-42. DOI: 10.1006/abbi.1994.1259. View

Kivisto K, Kroemer H, Eichelbaum M . The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol. 1995; 40(6):523-30. PMC: 1365206. DOI: 10.1111/j.1365-2125.1995.tb05796.x. View

Marre F, Sanderink G, De Sousa G, Gaillard C, Martinet M, Rahmani R . Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 1996; 56(6):1296-302. View

McKay J, Murray G, Weaver R, Ewen S, Melvin W, Burke M . Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut. 1993; 34(9):1234-9. PMC: 1375461. DOI: 10.1136/gut.34.9.1234. View

Sikic B, Fisher G, Lum B, Halsey J, Beketic-Oreskovic L, Chen G . Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997; 40 Suppl:S13-9. DOI: 10.1007/s002800051055. View

Walker D, Flinois J, Monkman S, Beloc C, Boddy A, Cholerton S . Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol. 1994; 47(7):1157-63. DOI: 10.1016/0006-2952(94)90387-5. View

Relling M, Nemec J, Schuetz E, Schuetz J, Gonzalez F, Korzekwa K . O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994; 45(2):352-8. View

10.

Henricsson S, Lindholm A, Aravoglou M . Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol. 1990; 66(1):49-52. DOI: 10.1111/j.1600-0773.1990.tb00701.x. View

11.

Rushing D, Raber S, Rodvold K, Piscitelli S, Plank G, TEWKSBURY D . The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer. 1994; 74(3):834-41. DOI: 10.1002/1097-0142(19940801)74:3<834::aid-cncr2820740308>3.0.co;2-9. View

12.

Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J . Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 1992; 6(2):752-8. DOI: 10.1096/fasebj.6.2.1371482. View

13.

Wacher V, Wu C, Benet L . Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995; 13(3):129-34. DOI: 10.1002/mc.2940130302. View

14.

Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F . Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol. 1991; 41(12):1911-9. DOI: 10.1016/0006-2952(91)90131-n. View

15.

Newton D, Wang R, Lu A . Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos. 1995; 23(1):154-8. View

16.

Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T . P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 1992; 51(18):1427-37. DOI: 10.1016/0024-3205(92)90537-y. View

17.

Purba H, Back D, Orme M . Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors. Br J Clin Pharmacol. 1987; 24(2):230-4. PMC: 1387755. DOI: 10.1111/j.1365-2125.1987.tb03167.x. View

18.

Bellamy W . P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996; 36:161-83. DOI: 10.1146/annurev.pa.36.040196.001113. View

19.

Newman M, Rodarte J, Benbatoul K, Romano S, Zhang C, Krane S . Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000; 60(11):2964-72. View

20.

Kerr D, Graham J, Cummings J, Morrison J, Thompson G, Brodie M . The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol. 1986; 18(3):239-42. DOI: 10.1007/BF00273394. View